机构：[1]Department of Endocrinology and Metabolism, The First Affiliated Hospital of China Medical University, Shenyang, China,[2]Department of Endocrinology, Chinese People’s Liberation Army (PLA) General Hospital, Beijing, China,[3]Department ofEndocrinology, Southwest Hospital, Third Military Medical University, Chongqing, China,[4]Department of Endocrinology, FirstAffiliated Hospital, Dalian Medical University, Dalian, China,[5]Department of Endocrinology, Cardiovascular andCerebrovascular Disease Hospital, General Hospital of Ningxia Medical University, Jinfeng, China,[6]Department ofEndocrinology and Metabolism, Second Affiliated Hospital of Nanchang University, Nanchang, China,[7]Department ofEndocrinology, First Affiliated Hospital of Harbin Medical University, Harbin, China,[8]Department of Endocrinology, HohhotFirst Hospital, Hohhot, China,[9]Department of Endocrinology and Metabolism, Second Xiangya Hospital, Central SouthUniversity, Changsha, China,[10]Research Center of Endocrine and Metabolic Diseases, Affiliated Hospital of IntegratedTraditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China,[11]Fujian Institute ofHematology, Union Hospital, Fujian Medical University, Fuzhou, China,[12]International Medical Center, The First AffiliatedHospital, Zhengzhou University, Zhengzhou, China,[13]Department of Endocrinology, First Affiliated Hospital of GuangxiMedical University, Nanning, China,[14]Department of Endocrinology, Hainan General Hospital, Haikou, China,[15]Departmentof Endocrinology, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China,[16]Department of Endocrinology, WuhanUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China,华中科技大学同济医学院附属协和医院[17]Department ofEndocrinology, First Hospital of Lanzhou University, Lanzhou, China,[18]State Key Laboratory of Biotherapy, West ChinaHospital, Sichuan University, Chengdu, China,[19]Department of Endocrinology and Metabolism, First Affiliated Hospital ofJilin University, Changchun, China,[20]Department of Endocrinology, Zhoupu Hospital, Shanghai University of Medicine andHealth Sciences, Shanghai, China,[21]Department of Endocrinology, First Affiliated Hospital of Anhui Medical University, Hefei,China,[22]Department of Endocrinology, The First People’s Hospital of Yunnan Province, Kunming, China,内科片内分泌科云南省第一人民医院[23]Department ofOtolaryngology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China,中山大学附属第二医院[24]Department of Endocrinology,First Hospital of Shanxi Medical University, Taiyuan, China,[25]Department of Endocrinology and Metabolism, People’sHospital of Tibet Autonomous Region, Lhasa, China,[26]Department of Endocrinology, Qinghai Provincial People’s Hospital,Xining, China,[27]Zhejiang Center for Disease Control and Prevention (Zhejiang CDC), Hangzhou, China,[28]Department ofEndocrinology and Metabolism, Affiliated Hospital of Guiyang Medical University, Guiyang, China,[29]Department ofEndocrinology, Second Hospital of Hebei Medical University, Shijiazhuang, China,[30]Department of Endocrinology, The FirstAffiliated Hospital of Xinjiang Medical University, Urumqi, China,[31]Department of Endocrinology and Metabolism, TianjinMedical University General Hospital, Tianjin, China
Background: Universal salt iodization (USI) was implemented in mainland China in 1996. The prevalence of hyperthyroidism and its risk factors now require examination. Methods: Data were acquired from a nationwide Thyroid, Iodine, and Diabetes Epidemiological survey (TIDE 2015-2017) of 78,470 subjects from 31 provinces. Iodine status, and thyroid hormones and antibodies were measured. Results: After two decades of USI, the prevalence of overt hyperthyroidism (OH), Graves' disease (GD), severe subclinical hyperthyroidism (severe SCH), and mild subclinical hyperthyroidism (mild SCH) in mainland China was 0.78%, 0.53%, 0.22%, and 0.22%, respectively. OH and GD prevalence were higher in women than in men (OH: 1.16% vs. 0.64%, Pvs. 0.37%, P<0.001).Prevalence was significantly decreased after 60 years-of-age compared with 30-39 years-of-age (OH:0.61% vs. 0.81%, Pvs. 0.57%, P<0.001).Excessive iodine(EI) and deficient iodine(DI) were both related to increased prevalence of OH (odds ratio [OR] 2.09, 95% confidence interval [CI] 1.68-2.59; OR1.35, 95%CI 1.07-1.72, respectively); however, only deficient iodine was associated with increased prevalence of GD (OR1.67, 95%CI 1.30-2.15). Increased thyroid peroxidase antibody and thyroglobulin antibody levels were significantly associated with prevalence of OH and GD, but not severe SCH and mild SCH. Although hyperthyroidism was more prevalent in women, the association disappeared after adjusting for other factors such as antibody levels. Conclusion: OH and GD prevalences in mainland China are stable after two decades of USI. Iodine deficiency, elevated thyroid antibody levels, and middle age are the main risk factors for OH and GD. The severe SCH population, rather than the mild SCH population, shows similar characteristics to the OH population.
基金：
Research Fund for Public Welfare, National Health and Family Planning Commission of China [201402005]
第一作者机构：[1]Department of Endocrinology and Metabolism, The First Affiliated Hospital of China Medical University, Shenyang, China,
通讯作者：
推荐引用方式(GB/T 7714)：
Chuyuan Wang,Yongze Li,Di Teng,et al.Hyperthyroidism Prevalence in China After Universal Salt Iodization[J].FRONTIERS IN ENDOCRINOLOGY.2021,12:doi:10.3389/fendo.2021.651534.
APA：
Chuyuan Wang,Yongze Li,Di Teng,Xiaoguang Shi,Jianming Ba...&Weiping Teng.(2021).Hyperthyroidism Prevalence in China After Universal Salt Iodization.FRONTIERS IN ENDOCRINOLOGY,12,
MLA：
Chuyuan Wang,et al."Hyperthyroidism Prevalence in China After Universal Salt Iodization".FRONTIERS IN ENDOCRINOLOGY 12.(2021)
